pMMR胃肠道肿瘤伴肿瘤浸润淋巴细胞（TIL）患者的治疗：现实？

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-07-01 Epub Date: 2025-05-28 DOI:10.1016/j.trecan.2025.05.004

John B Haanen

{"title":"pMMR胃肠道肿瘤伴肿瘤浸润淋巴细胞（TIL）患者的治疗：现实？","authors":"John B Haanen","doi":"10.1016/j.trecan.2025.05.004","DOIUrl":null,"url":null,"abstract":"A recent study published in Nature Medicine shows that adoptive cell therapy using neoantigen-selected tumor-infiltrating lymphocytes (TIL) is feasible in refractory metastatic gastrointestinal (GI) cancers, showing durable responses, especially when combined with anti-PD-1. Despite low tumor mutational burden (TMB), enriched neoantigen-reactive TIL improved objective response rates (ORR), highlighting the role of the tumor microenvironment and supporting further clinical development.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"614-615"},"PeriodicalIF":17.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?\",\"authors\":\"John B Haanen\",\"doi\":\"10.1016/j.trecan.2025.05.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A recent study published in Nature Medicine shows that adoptive cell therapy using neoantigen-selected tumor-infiltrating lymphocytes (TIL) is feasible in refractory metastatic gastrointestinal (GI) cancers, showing durable responses, especially when combined with anti-PD-1. Despite low tumor mutational burden (TMB), enriched neoantigen-reactive TIL improved objective response rates (ORR), highlighting the role of the tumor microenvironment and supporting further clinical development.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"614-615\"},\"PeriodicalIF\":17.5000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2025.05.004\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2025.05.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

最近发表在《自然医学》杂志上的一项研究表明，使用新抗原选择的肿瘤浸润淋巴细胞（TIL）的过继细胞治疗在难治性转移性胃肠道（GI）癌症中是可行的，表现出持久的反应，特别是与抗pd -1联合使用时。尽管肿瘤突变负担（TMB）较低，但富集的新抗原反应性TIL提高了客观反应率（ORR），突出了肿瘤微环境的作用，并支持进一步的临床发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?

A recent study published in Nature Medicine shows that adoptive cell therapy using neoantigen-selected tumor-infiltrating lymphocytes (TIL) is feasible in refractory metastatic gastrointestinal (GI) cancers, showing durable responses, especially when combined with anti-PD-1. Despite low tumor mutational burden (TMB), enriched neoantigen-reactive TIL improved objective response rates (ORR), highlighting the role of the tumor microenvironment and supporting further clinical development.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.